LSD1/HDAC6-IN-2

LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma[1][2].

Product Specifications

CAS Number

[2982787-50-6]

UNSPSC

12352005

Target

HDAC; Histone Demethylase; Monoamine Oxidase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lsd1-hdac6-in-2.html

Purity

99.66

Solubility

DMSO : ≥ 100 mg/mL

Smiles

ONC(C(C=C1)=CC=C1CN(N=C2)C=C2CN[C@H]3[C@H](C4=CC=CC=C4)C3)=O.[H]Br

Molecular Formula

C21H23BrN4O2

Molecular Weight

443.34

References & Citations

[1]Yang X. Research progress of LSD1-based dual-target agents for cancer therapy. Bioorg Med Chem. 2024 Mar 1;101:117651. |[2]Sivanandhan D, et al. JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer[J]. Cancer Research, 2020, 80 (16_Supplement) : 1756-1756.